In a phase 3 clinical trial (NCT05438407) among children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), leniolisib (Joenja; Pharming Group N.V.) demonstrated ...

The Centers for Disease Control and Prevention (CDC) views COVID-19 asan endemic virus. 1 Essentially it is circulating inperpetuityand we will witnessebbs and flows in prevalence.And certainly during ...

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year. It was also great to speak with international practitioners, advanced practice ...

A good correlation and statistical agreement with total serum bilirubin was observed in a study of a new smartphone-based machine learning app, leaving it a potential neonatal jaundice screening tool.

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg). In a study that assessed 3 randomized clinical trials of adolescents with moderate-to-severe ...

In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir. In this episode, the panel ...

Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA. Positive, topline phase 2 trial results for ...

Respondents reported decreased diarrhea severity, improved patient quality of life, and decreased treatment discontinuation among patients with Rett syndrome treated with trofinetide. Data from a ...

PIF Partners recently announced that 101-PGC-005 (‘005), a proprietary investigational therapeutic for the treatment of systemic juvenile idiopathic arthritis (sJIA) flares, has received Rare ...

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years. Positive phase 3 data for fremanezumab (Ajovy;Teva Pharmaceutical Industries) has been reported for ...

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution. A New Drug Application SL1009, Sodium Dichloroacetate Oral Solution (DCA ...

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older. A pair of supplemental Biologics License Applications (sBLAs) ...